ASCO 2017: STAMPEDE Trial: Adding Abiraterone to Standard Treatment Improves Survival in Advanced Prostate Cancer

Key Points

  • At a median follow-up of 40 months, 262 deaths had occurred in the standard therapy group and 184 deaths had occurred in the abiraterone group.
  • The 3-year overall survival rate was 83% in the abiraterone group vs 76% in the standard therapy group.
  • Abiraterone lowered the relative chance of treatment failure (measured by worsening scans or symptoms or elevated prostate-specific antigen level) by 71% compared with standard therapy.

The STAMPEDE clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone vs 83% with standard therapy plus abiraterone. This is the largest study of abiraterone as first-line therapy for advanced prostate cancer. The study was presented today by James et al at the 2017 ASCO Annual Meeting (Abstract LBA5003).

“Abiraterone not only prolonged life, but also lowered the chance of relapse by 70% and reduced the chance of serious bone complications by 50%,” said lead study author Nicholas James, BSc, MBBS, PhD, Professor of Clinical Oncology at Queen Elizabeth Hospital in Birmingham, United Kingdom. “Based on the magnitude of clinical benefit, we believe that the upfront care for patients newly diagnosed with advanced prostate cancer should change.”

About the Study

STAMPEDE is an ongoing multiarm, multistage randomized clinical trial conducted in the United Kingdom and Switzerland. The current analysis compared standard therapy with standard therapy plus abiraterone in men with high-risk prostate cancer who were starting androgen-deprivation therapy. The men had either locally advanced or metastatic cancer, and all were commencing long-term standard androgen-deprivation therapy for the first time. The standard therapy consisted of androgen-deprivation therapy for at least 2 years; men with locally advanced cancer (48% of all patients) could also receive radiation therapy in addition to androgen-deprivation therapy. A novel approach to the clinical trial design meant this comparison recruited patients much more quickly than most academic-led trials, and STAMPEDE will report randomized data from at least 10 comparisons over 2 decades.

Key Findings

At a median follow-up of 40 months, 262 deaths had occurred in the standard therapy group and 184 deaths had occurred in the abiraterone group. The 3-year overall survival rate was 83% in the abiraterone group vs 76% in the standard therapy group. Abiraterone lowered the relative chance of treatment failure (measured by worsening scans or symptoms, or elevated prostate-specific antigen level) by 71% compared with standard therapy. The effects were consistent across the different subgroups of people enrolled in the trial.

Overall, side effects were similar between the two groups. Severe side effects were more common in the abiraterone group, occurring in 41% of patients compared with 29% of patients in the standard therapy group. The main side effects occurring more frequently with abiraterone were cardiovascular problems such as high blood pressure; there were also more liver problems with abiraterone. There were two treatment-related deaths in the abiraterone group and one in the standard therapy group.

Commentary

“This study provides strong evidence to support adding abiraterone to standard hormone therapy, primarily for men with metastatic prostate cancer. It adds to a growing body of evidence that establishes abiraterone as a standard of care in this setting,” said ASCO expert Sumanta Kumar Pal, MD.

This study was funded by grants from Cancer Research UK, the Medical Research Council, and Janssen, with additional contributions to the STAMPEDE protocol from Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement